{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:37:19Z","timestamp":1791434239462,"version":"4.3.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1038\/bjc.2012.385","type":"journal-article","created":{"date-parts":[[2012,11,7]],"date-time":"2012-11-07T00:05:27Z","timestamp":1352246727000},"page":"1665-1671","source":"Crossref","is-referenced-by-count":93,"title":["Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases"],"prefix":"10.1038","volume":"107","author":[{"given":"B","family":"Beuselinck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Wolter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Karadimou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Elaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Dumez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rogiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Van Cann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-J","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Berkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Van Poppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Lerut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Debruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Paridaens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,6]]},"reference":[{"issue":"3","key":"BFbjc2012385_CR1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/annonc\/mdn788","volume":"20","author":"J Ayllon","year":"2009","unstructured":"Ayllon J, Launay-Vacher V, Medioni J, Cros C, Spano JP, Oudard S (2009) Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol 20 (3): 600\u2013601","journal-title":"Ann Oncol"},{"issue":"34","key":"BFbjc2012385_CR2","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (34): 8580\u20138587","journal-title":"J Clin Oncol"},{"issue":"4","key":"BFbjc2012385_CR3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/annonc\/mdq554","volume":"22","author":"B Beuselinck","year":"2011","unstructured":"Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Sch\u00f6ffski P, Barrascout E, Morel A, Escudier B, Lang H, Zucman-Rossi J, Medioni J (2011) \u2018Negative impact of bone metastasis on outcome in clear cell renal cell carcinoma treated with sunitinib\u2019. Ann Oncol 22 (4): 794\u2013800","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"BFbjc2012385_CR4","doi-asserted-by":"publisher","first-page":"e15116","DOI":"10.1200\/jco.2011.29.15_suppl.e15116","volume":"29","author":"G. Bozas","year":"2011","unstructured":"Bozas G, Allgar V, Greenwood G, Maraveyas A (2011) Osteonecrosis of the jaw in patients treated with sunitinib and zoledronic acid. J Clin Oncol 29 (Suppl): abstract e15116","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"BFbjc2012385_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000201931","volume":"76","author":"C Christodoulou","year":"2009","unstructured":"Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV (2009) Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76 (3): 209\u2013211","journal-title":"Oncology"},{"issue":"8","key":"BFbjc2012385_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10585-007-9112-8","volume":"24","author":"P Clezardin","year":"2007","unstructured":"Clezardin P, Teti A (2007) Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis 24 (8): 599\u2013608","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"BFbjc2012385_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2007a) TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2): 125\u2013134","journal-title":"N Engl J Med"},{"issue":"9605","key":"BFbjc2012385_CR8","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N, AVOREN Trial investigators (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (9605): 2103\u20132111","journal-title":"Lancet"},{"issue":"1","key":"BFbjc2012385_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","volume":"122","author":"V Guarneri","year":"2010","unstructured":"Guarneri V, Miles D, Robert N, Di\u00e9ras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122 (1): 181\u2013188","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"BFbjc2012385_CR10","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial (2007) Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (22): 2271\u20132281","journal-title":"N Engl J Med"},{"key":"BFbjc2012385_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"2006","author":"A Jemal","year":"2006","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 2006: 106\u2013130","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"BFbjc2012385_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ejca.2012.02.050","volume":"48","author":"D Keizman","year":"2012","unstructured":"Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger M, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA (2012) Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer 48 (7): 1031\u20131037","journal-title":"Eur J Cancer"},{"issue":"3","key":"BFbjc2012385_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00345-004-0466-0","volume":"23","author":"JS Lam","year":"2005","unstructured":"Lam JS, Leppert JT, Belldegrun AS, Figlin RA (2005) Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 23 (3): 202\u2013212","journal-title":"World J Urol"},{"issue":"9757","key":"BFbjc2012385_CR14","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","volume":"376","author":"GJ Morgan","year":"2010","unstructured":"Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Study Group (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376 (9757): 1989\u20131999","journal-title":"Lancet"},{"issue":"18 Part 2","key":"BFbjc2012385_CR15","first-page":"6202S","volume":"10","author":"R Motzer","year":"2004","unstructured":"Motzer R, Bacik J, Mazumbar M (2004) Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan Kettering Cancer Center experience. Clin Cancer Res 10 (18 Part 2): 6202S\u20136203S","journal-title":"Clin Cancer Res"},{"issue":"8","key":"BFbjc2012385_CR16","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","volume":"17","author":"R Motzer","year":"1999","unstructured":"Motzer R, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (8): 2530\u20132540","journal-title":"J Clin Oncol"},{"issue":"18","key":"BFbjc2012385_CR17","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gr\u00fcnwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A, RECORD-1 Study Group (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116 (18): 4256\u20134265","journal-title":"Cancer"},{"issue":"9637","key":"BFbjc2012385_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gr\u00fcnwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, RECORD-1 Study Group (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (9637): 449\u2013456","journal-title":"Lancet"},{"issue":"2","key":"BFbjc2012385_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2): 115\u2013124","journal-title":"N Engl J Med"},{"issue":"2","key":"BFbjc2012385_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55 (2): 74\u2013108","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"BFbjc2012385_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/annonc\/mdq342","volume":"22","author":"S Patil","year":"2011","unstructured":"Patil S, Figlin R, Hutson T, Michaelson M, N\u00e9grier S, Kim T, Huang X, Motzer R (2011) Prognostic factors for progression free survival and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22 (2): 295\u2013300","journal-title":"Ann Oncol"},{"issue":"2","key":"BFbjc2012385_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/COC.0b013e3181574084","volume":"31","author":"R Riechelmann","year":"2008","unstructured":"Riechelmann R, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, Knox JJ (2008) Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am J Clin Oncol 31 (2): 182\u2013187","journal-title":"Am J Clin Oncol"},{"issue":"16","key":"BFbjc2012385_CR23","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21 (16): 3150\u20133157","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"BFbjc2012385_CR24","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1053\/j.seminoncol.2010.06.001","volume":"37","author":"F Saad","year":"2010","unstructured":"Saad F, Eastham JA (2010) Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol 37 (Suppl 1): S38\u2013S44","journal-title":"Semin Oncol"},{"key":"BFbjc2012385_CR25","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1464-410X.2005.05740.x","volume":"96","author":"F Saad","year":"2005","unstructured":"Saad F, Lipton A (2005) Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 96: 964\u2013969","journal-title":"BJU Int"},{"key":"#cr-split#-BFbjc2012385_CR26.1","unstructured":"1. US National Institutes of Health (2006) Surveillance, epidemiology and end results (SEER) cancer statistics review. Kidney and Renal Pelvis Cancer 5-year Relative Survival Rates, 1996-2002"},{"key":"#cr-split#-BFbjc2012385_CR26.2","unstructured":"2.   http:\/\/seer.cancer.gov\/cgi-bin\/csr\/1975_2003\/search.pl#results    (September 2006)"},{"issue":"4","key":"BFbjc2012385_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","volume":"15","author":"MS Zaghloul","year":"2010","unstructured":"Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M (2010) A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15 (4): 382\u2013389","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"BFbjc2012385_CR28","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1002\/ijc.24470","volume":"125","author":"K Zarogoulidis","year":"2009","unstructured":"Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G, Kanakis I, Karamanos NK (2009) The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 125 (7): 1705\u20131709","journal-title":"Int J Cancer"},{"key":"BFbjc2012385_CR29","first-page":"379","volume":"19","author":"J Zekri","year":"2001","unstructured":"Zekri J, Ahmed N, Coleman RE, Hancock BW (2001) The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19: 379\u2013382","journal-title":"Int J Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2012385.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2012385","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2012385.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:10:10Z","timestamp":1684415410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2012385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["BFbjc2012385"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2012.385","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}